A phase 2 trial with LY3056480 in patients with stable SNHL
VESTA is a double blinded, randomized, placebo controlled, multi center efficacy phase 2 study comparing three dosing regimens of 250 µg LY3056480. Adult volunteers with stable mild to moderately-severe SNHL will be recruited through Adult Otolaryngology - Head \& Neck Surgery Services in the US. Four injections of 250µg LY3056480 or placebo administered trans-tympanically into one ear (worse hearing ear).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
LY3056480 is an inhibitor of gamma-secretase
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
New York Eye and Ear Infirmary ICAHN school of Medicine Mount Sinai
New York, New York, United States
Eastern Virginia Medical School
Norfolk, Virginia, United States
the efficacy of local treatment with LY3056480 in terms of hearing function
• Number of drug responders with at least a 2dB improvement in an adaptive sentence in noise test (international matrix test) compared to placebo
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.